Tuesday, December 23, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Wegovy pill approved by US FDA for weight loss

December 23, 2025
in Health News
Share on FacebookShare on Twitter


The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk.

It is the first pill of its kind to receive approval from the regulator, marking a new era for weight-loss drugs.

Wegovy’s Danish makers Novo Nordisk said the once-daily pill was a “convenient option” to the injectable and would provide the same weight loss as the shot. It comes after Wegovy was approved by the FDA specifically for weight loss.

Others like Ozempic, which has similar weight-loss effects, were primarily approved for the treatment of Type 2 diabetes.

The BBC has contacted the FDA for comment.

The Wegovy pill showed an average weight loss of 16.6% during Novo Nordisk’s trials, the firm said on Monday.

A third of around 1,300 participants experienced 20% or greater weight loss in the same trial, it added.

The pill is expected to be launched in the US in early January 2026.

“Patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Mike Doustdar, the firm’s chief executive.

The pill version of Wegovy could give Novo Nordisk’s sales a boost after a challenging year which saw its shares slide as it warned over its profits.

The company has faced intense competition in the weight-loss market from rival drugmakers like Eli Lilly.

Novo Nordisk’s shares rose by almost 10% in after-hours trade in New York after the announcement.



Source link : https://www.bbc.com/news/articles/ce86le5dyxyo?at_medium=RSS&at_campaign=rss

Author :

Publish date : 2025-12-23 01:29:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

Next Post

Apremilast Shows Sustained Benefit for Genital Psoriasis

Related Posts

Health News

FcRn Blockers Vie to Become First Approved Drug for Sjogren’s Disease

December 23, 2025
Health News

EU Calls for Heart Health Plans Amid Rising Disease Burden

December 23, 2025
Health News

Here’s Where Measles Case Counts Are Highest

December 23, 2025
Health News

How Is Frailty Linked With Cardiovascular Disease Events?

December 23, 2025
Health News

Medicare’s New WISeR Spending Model: 5 Things to Know

December 23, 2025
Health News

Gene therapy for Huntington’s disease showed great promise in 2025

December 23, 2025
Load More

FcRn Blockers Vie to Become First Approved Drug for Sjogren’s Disease

December 23, 2025

EU Calls for Heart Health Plans Amid Rising Disease Burden

December 23, 2025

Here’s Where Measles Case Counts Are Highest

December 23, 2025

How Is Frailty Linked With Cardiovascular Disease Events?

December 23, 2025

Medicare’s New WISeR Spending Model: 5 Things to Know

December 23, 2025

Gene therapy for Huntington’s disease showed great promise in 2025

December 23, 2025

Antipsychotic Use Surges Among Older US Adults

December 23, 2025

FDA: BMD Can Be Surrogate Endpoint in Osteoporosis Trials

December 23, 2025
Load More

Categories

Archives

December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
« Nov    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version